Literature DB >> 22099874

Therapeutic approaches targeting midkine suppress tumor growth and lung metastasis in osteosarcoma.

Takanao Sueyoshi1, Hirofumi Jono, Satoru Shinriki, Kazutoshi Ota, Tomoko Ota, Masayoshi Tasaki, Eri Atsuyama, Toshitake Yakushiji, Mitsuharu Ueda, Konen Obayashi, Hiroshi Mizuta, Yukio Ando.   

Abstract

Midkine (MK) plays important roles in tumorigenesis, however, the biological function of MK and whether MK can be a therapeutic target in osteosarcoma are unclear. Here, we found that osteosarcoma tissues showed high MK expression. MK knockdown by small interfering RNA significantly induced apoptosis in osteosarcoma cells, whereas recombinant MK increased cell proliferation. Inhibition of MK signaling by anti-MK monoclonal antibody (anti-MK mAb) suppressed growth of osteosarcoma cells both in vitro and in vivo. Moreover, inhibition of MK function significantly suppressed lung metastasis in xenograft transplantation model. Targeting MK by anti-MK mAb may have value in the treatment of osteosarcoma.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22099874     DOI: 10.1016/j.canlet.2011.10.013

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  12 in total

Review 1.  Involvement of midkine in neuroblastoma tumourigenesis.

Authors:  S Kishida; K Kadomatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

2.  Midkine silencing enhances the anti-prostate cancer stem cell activity of the flavone apigenin: cooperation on signaling pathways regulated by ERK, p38, PTEN, PARP, and NF-κB.

Authors:  Suat Erdogan; Kader Turkekul; Ilker Dibirdik; Zeynep B Doganlar; Oguzhan Doganlar; Ayhan Bilir
Journal:  Invest New Drugs       Date:  2019-04-16       Impact factor: 3.850

Review 3.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

Review 4.  Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.

Authors:  Panagiota S Filippou; George S Karagiannis; Anastasia Constantinidou
Journal:  Oncogene       Date:  2019-12-04       Impact factor: 9.867

5.  Survivin and vascular endothelial growth factor are associated with spontaneous pulmonary metastasis of osteosarcoma: Development of an orthotopic mouse model.

Authors:  Li Zhang; Youyou Ye; Dejian Yang; Jianhua Lin
Journal:  Oncol Lett       Date:  2014-09-24       Impact factor: 2.967

6.  The Protein Tyrosine Phosphatase Rptpζ Suppresses Osteosarcoma Development in Trp53-Heterozygous Mice.

Authors:  Christina Baldauf; Anke Jeschke; Vincent Kanbach; Philip Catala-Lehnen; Daniel Baumhoer; Helwe Gerull; Sophia Buhs; Michael Amling; Peter Nollau; Sheila Harroch; Thorsten Schinke
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

7.  Midkine, a potential link between obesity and insulin resistance.

Authors:  Nengguang Fan; Haiyan Sun; Yifei Wang; Lijuan Zhang; Zhenhua Xia; Liang Peng; Yanqiang Hou; Weiqin Shen; Rui Liu; Yongde Peng
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

8.  The effect of electroacupuncture on osteosarcoma tumor growth and metastasis: analysis of different treatment regimens.

Authors:  Branden A Smeester; Mona Al-Gizawiy; Elaine E O'Brien; Marna E Ericson; Jennifer L Triemstra; Alvin J Beitz
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-21       Impact factor: 2.629

9.  LncRNA SNHG10 increases the methylation of miR-218 gene to promote glucose uptake and cell proliferation in osteosarcoma.

Authors:  Pan He; Yongqiang Xu; Zhijun Wang
Journal:  J Orthop Surg Res       Date:  2020-08-26       Impact factor: 2.359

10.  Changes of serum midkine as a dynamic prognostic factor to monitor disease status in papillary thyroid cancer.

Authors:  Ning Li; Chunmei Zhang; Zhaowei Meng; Ke Xu; Xianghui He; Yang Yu; Qiang Jia; Xue Li; Xiangxiang Liu; Xiaoran Wang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.